Abstract This study has been conducted on 62 decompensated cardiacs who were subjected to diuresis with four mercurial diuretics. Studies on weight loss and days required to return to dry weight revealed a small difference between meralluride, mercaptomerin, mercumatilin and merethoxylline, which was not significant, indicating that these drugs may be used interchangeably. The serum electrolytes of these patients revealed no significant difference from those of other hospital patients. Following diuresis with mercurials to dry weight, no clinically significant differences were noted in the sodium serum levels, except in the case of mercuhydrin where there was a statistically significant decrease in the serum sodium level. This was not within the pathologic range nor did it result in hyponatremia except in two cases noted in patients with far-advanced congestive failure, cor bovinum and myocardial degeneration. Two cases of medicamentosa dermatitis with thiomerin were also found which responded promptly to withdrawal of the mercurial and substitution of a non-mercurial diuretic. It is felt that the low sodium syndrome cannot be related to any one mercurial diuretic but rather to the method in which the diuretic is used in the treatment of congestive failure.

01 Apr 1957·Annals of the New York Academy of SciencesQ2 · CROSS-FIELD

BIOASSAY OF ORGANOMERCURIALS

Q2 · CROSS-FIELD

Article

Author: Theodore H. Greiner

Most methods of determining the response of ambulatory patients to mercurial and other diuretics entail certain difficulties, even measuring the volume of urine or determining the amount of NaCl excreted may be inconvenient.G. determines the weight of the patient before and 2 days after intramuscular injection of meralluride (I).The loss of weight (body water) in response to different doses indicates the amount that should be given.If it is desired to use diuretics other than I, the amounts required can be estimated from a table in which such compounds are listed in terms of diuretic potency in terms of I.With I assumed to have a potency of 100%, the intramuscular efficiencies of other diuretics decrease in the order: mercurophylline 98, mercaptomerin 88, merethoxylline 82, salyrgantheophylline 75, and mercumatilin 76%.In congestive heart failure, I potentiates the action of NH₄Cl in causing water elimination.Though not commonly used by injection, chlormerodrin (II) when injected showed a potency of 250% in comparison with I.When given orally, relative diuretic efficiency increased in the order: I 81, aminometradine (III) 254, II 284, and aminoisometradine (IV) 351.II is the least irritating mercurial diuretic.III and IV are nonmercurial diuretics of high efficiency.

21 Aug 1954·Journal of the American Medical Association

NEW AND nonofficial remedies: merethoxylline procaine.

Article

100 Deals associated with Procaine merethoxylline

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Procaine merethoxylline

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation